| VIKING THERAPEUTICS |
| USA |
| Gesundheit |
| US92686J1060 / A12GD6 |
| 1VT (Frankfurt) / VKTX (NASDAQ) |
| FRA:1VT, ETR:1VT, 1VT:GR, NASDAQ:VKTX |
| - |
| https://www.vikingtherape.. |
|
Viking Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and endocrine disorders. Headquartered in San Diego, California, Viking concentrates on mechanism-driven drug candidates target..
>Volltext.. |
| 3694.89 Mio. EUR |
| 3172.42 Mio. EUR |
| - |
| -438.89 Mio. EUR |
| -413.29 Mio. EUR |
| -3.63 EUR |
| - |
| 103.35 Mio. EUR |
| -297.79 Mio. EUR |
| 5.67 |
| - |
| -244.89% |
| - |
| - |
| - |
| - |
| VIKING THERAPEUTICS, VIKING THERAPEUTIC |
| 17.07.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|